Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China

Li, Meng; Liao, Yong; Chen, Min; Pan, Weihua; Weng, Lixing

doi:10.1016/S1413-8670(12)70301-X

Article information

Abstract

Cryptococcus spp. are common causes of mycoses in immunocompromised patients. To determine the drug susceptibilities of clinical Cryptococcus spp. isolates, the characteristics of 61 clinical Cryptococcus spp. complex isolates and their antifungal susceptibilities were investigated, including 52 C. neoformans and 9 C. gattii isolates collected at Shanghai between 1993 and 2009. Antifungal susceptibility of clinical isolates to amphotericin B, fluconazole, itraconazole, and flucytosine were determined by the microdilution method M27-A2 and the ATB FUNGUS 3 kit. The 90% minimum inhibitory concentration (MIC90) and susceptibility ranges were as follows: 1 (0.0625–1) μg/mL for amphotericin B, 4 (0.125–16) μg/mL for fluconazole, 0.25 (0.0313–4) μg/mL for itraconazole, and 4 (0.125–8) μg/mL for flucytosine. Fluconazole, itraconazole, and flucytosine have excellent in vitro activity against all tested clinical Cryptococcus spp., and we also found a high rate of tolerance to amphotericin B (MICs ranging from 0.55–1μg/mL). Furthermore, C. neoformans isolates from acquired immune deficiency syndrome (AIDS) patients were less susceptible to fluconazole and flucytosine than those from non-AIDS patients. These data suggest that use of amphotericin B may lead to tolerance or resistance of the pathogen over time. There were also no significant associations between species, genotypes, and in vitro susceptibilities of these clinical isolates.

Keywords:

Cryptococcus neoformans

Cryptococcus gattii

Antifungal agents

Full text is only aviable in PDF

References

[1.]

K.J. Kwon-Chung, A. Varma.

Do major species concepts support one, two or more species within Cryptococcus neoformans?.

FEMS Yeast Res, 6 (2006), pp. 574-587

http://dx.doi.org/10.1111/j.1567-1364.2006.00088.x | Medline

[2.]

S.A. Mirza, M. Phelan, D. Rimland, et al.

The changing epidemiology of cryptococcosis: an update from populationbased active surveillance in 2 large metropolitan areas, 1992–2000.

Clin Infect Dis, 36 (2003), pp. 789-794

http://dx.doi.org/10.1086/368091 | Medline

[3.]

M. Chen, X.R. Li, S.X. Wu, et al.

Molecular epidemiology of Cryptococcus neoformans species complex isolates from HIV-positive and HIV-negative patients in southeast China.

Frontiers of Medicine in China, 4 (2010), pp. 117-126

[4.]

Z. Yao, W. Liao, R. Chen.

Management of cryptococcosis in non-HIV-related patients.

Med Mycol, 43 (2005), pp. 245-251

Medline

[5.]

F. Dromer, S. Mathoulin-Pélissier, A. Fontanet, et al.

Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras.

AIDS, 18 (2004), pp. 555-562

Medline

[6.]

N. Iqbal, E.E. DeBess, R. Wohrle, et al.

Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States.

J Clin Microbiol, 48 (2010), pp. 539-544

http://dx.doi.org/10.1128/JCM.01505-09 | Medline

[7.]

Y.C. Chen, S.C. Chang, C.C. Shih, et al.

Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan.

Diagn Microbiol Infect Dis, 36 (2000), pp. 175-183

Medline

[8.]

L.P. Zhu, C. Gil-Lamaignere, F.M. Müller.

Effects of several antifungal drug combinations against clinical and environmental isolates of Cryptococcus neoformans from China.

Mycoses, 47 (2004), pp. 319-325

http://dx.doi.org/10.1111/j.1439-0507.2004.00998.x | Medline

[9.]

National Committee for Clinical Laboratory Standards.

Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A2.

NCCLS, (2002),

[10.]

K. Datta, N. Jain, S. Sethi, et al.

Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care.

J Antimicrob Chemother, 52 (2003), pp. 683-686

http://dx.doi.org/10.1093/jac/dkg399 | Medline

[11.]

S.T. Tay, T. Tanty Haryanty, K.P. Ng, et al.

In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.

Mycoses, 49 (2006), pp. 324-330

http://dx.doi.org/10.1111/j.1439-0507.2006.01242.x | Medline

[12.]

B. Sar, D. Monchy, M. Vann, et al.

Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.

J Antimicrob Chemother, 54 (2004), pp. 563-565

http://dx.doi.org/10.1093/jac/dkh361 | Medline

[13.]

A.M. Almeida, M.T. Matsumoto, L.C. Baeza, et al.

Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil.

FEMS Yeast Res, 7 (2007), pp. 152-164

http://dx.doi.org/10.1111/j.1567-1364.2006.00128.x | Medline

[14.]

J. Chandenier, K.D. Adou-Bryn, C. Douchet, et al.

In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia.

Eur J Clin Microbiol Infect Dis, 23 (2004), pp. 506-508

http://dx.doi.org/10.1007/s10096-004-1136-2 | Medline

[15.]

M.C. Pappalardo, M.W. Szeszs, M.A. Martins, et al.

Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.

Diagn Microbiol Infect Dis, 64 (2009), pp. 146-151

http://dx.doi.org/10.1016/j.diagmicrobio.2009.02.007 | Medline

[16.]

M. Lozano-Chiu, V.L. Paetznick, M.A. Ghannoum, J.H. Rex.

Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies.

J Clin Microbiol, 36 (1998), pp. 2817-2822

Medline

[17.]

A. Perkins, A. Gomez-Lopez, E. Mellado, J.L. Rodriguez-Tudela, M. Cuenca-Estrella.

Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.

J Antimicrob Chemother, 56 (2005), pp. 144-147

[18.]

J. Morgan, K.M. McCarthy, S. Gould, et al.

Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002–2004.

Clin Infect Dis, 43 (2006), pp. 1077-1080

http://dx.doi.org/10.1086/507897 | Medline

[19.]

A. Gomez-Lopez, O. Zaragoza, M. Dos Anjos Martins, et al.

In vitro susceptibility of Cryptococcus gattii clinical isolates.

Clin Microbiol Infect, 14 (2008), pp. 727-730

http://dx.doi.org/10.1111/j.1469-0691.2008.02021.x | Medline

[20.]

B.J. Kullberg, J.D. Sobel, M. Ruhnke, et al.

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

Lancet, 366 (2005), pp. 1435-1442

http://dx.doi.org/10.1016/S0140-6736(05)67490-9 | Medline

[21.]

R.P. Hardiman, D.J. Marriott, S. Chen, et al.

The development of amphotericin B resistant Cryptococcus neoformans during treatment of cryptococcal meningitis in an HIV-infected patient.

Annu Conf Australas Soc HIV Med, 8 (1996), pp. 14-17

1

Both authors contributed equally to this work.

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter